Summit Securities Group’s Editas Medicine EDIT Stock Holding History

Summit Securities Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,000	Closed	-$49K	–	1208
2022 Q3	$49K	Buy	+4,000	New	+$62.3K	﹤0.01%	619

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Summit Securities Group's EDIT Position: Q2 2025 in Review

Summit Securities Group sold out of Editas Medicine (EDIT) in Q2 2025, closing a stake of 178 shares — an estimated $206 sold.

Summit Securities Group first reported a position in EDIT in Q3 2023 and held it in 2 quarters. The position peaked at $44K in Q3 2023. 193 funds tracked by Wall St. Rank hold EDIT as of Q2 2025.

Summit Securities Group reported no remaining Editas Medicine position as of Q2 2025 after selling out during the quarter.
Summit Securities Group sold 178 Editas Medicine shares in Q2 2025, an estimated $206.
Summit Securities Group first reported a position in Editas Medicine in Q3 2023 and held it in 2 quarters.
Summit Securities Group's Editas Medicine position peaked at $44K in Q3 2023.
193 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.